HLX10 + carboplatin + nab-paclitaxel

HLX10 + carboplatin + nab-paclitaxel is a **three-drug combination therapy** under clinical investigation primarily for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sNSCLC)[5]. - **HLX10** is a recombinant, fully humanized anti-PD-1 IgG4 monoclonal antibody. It blocks PD-1, a checkpoint protein on T cells, releasing the "brakes" on the immune system and enhancing T-cell mediated anti-tumor responses[1][3][7]. HLX10 is developed as a novel immunotherapy potentially comparable or superior to existing PD-1 inhibitors like nivolumab and pembrolizumab[3]. - **Carboplatin** is a platinum-based chemotherapy agent that crosslinks DNA, preventing replication and inducing apoptosis, frequently used in solid tumor chemotherapy. - **Nab-paclitaxel** is an albumin-bound nanoparticle formulation of paclitaxel. It acts as an antimicrotubule agent, stabilizing microtubules and interfering with mitosis. Nab-paclitaxel increases delivery to tumors via albumin-mediated transcytosis and binding to SPARC, resulting in greater intratumoral accumulation[2][4][6]. The combination aims to synergistically combine immune checkpoint blockade (HLX10) with cytotoxic chemotherapy to enhance anti-tumor activity. HLX10 is developed by Shanghai Henlius Biotech. Nab-paclitaxel's most recognized brand name is Abraxane, developed by American BioScience and distributed by Bristol Myers Squibb.

Brand names

HANSIZHUANG

Other names

nanoparticle albumin-bound paclitaxelpaclitaxel protein bound